7月28日晚间，ST华西（002630）(原证券简称华西能源，SZ002630，股价2.57元，市值30.35亿元)发布 公告称，公司董事会于当日收到董秘孟海涛的书面辞职报告。孟海涛因个人原因辞去所担任的公司董秘 职务，辞职后，孟海涛仍将继续在公司担任董事、副总裁、财务总监等职务。董事会秘书空缺期间，由 公司董事长黄有全代行董事会秘书职责。 华西能源公告称，孟海涛未持有公司股份，不涉及股份锁定承诺事项。7月28日晚间，孟海涛对《每日 经济新闻》记者表示，此次辞去董秘职务是因为此前其遭到了深交所的公开谴责处分。 公司近年连续亏损 过去数年来，华西能源连年亏损。2020年~2024年，公司归母净利润分别为-4.66亿元、-6.82亿元、-7.57 亿元、-1.93亿元和-3.48亿元，五年累计亏损金额约24.46亿元。而2023年和2024年，公司营收还分别实 现了117.30%和38.91%的增长，即便如此，公司仍未走出亏损泥潭。 6月30日，深交所发布关于对华西能源及相关当事人给予公开谴责处分的决定。华西能源所涉主要违规 事项，便是2024年度业绩预告与经审计净利润存在重大差异，盈亏性质发生变化。 《每日经济 ...

Core Viewpoint - The second largest shareholder of Koyuan Pharmaceutical plans to reduce its stake in the company, which has led to a significant drop in the company's stock price following the announcement [1][2]. Group 1: Shareholder Actions - Koyuan Pharmaceutical announced that its second largest shareholder, Wen Zehong, who holds 8.4 million shares (7.76% of total shares), intends to reduce his holdings by up to 3% of the total shares, equating to a maximum of 3.2487 million shares [1]. - The reduction is attributed to Wen Zehong's personal funding needs, with the shares being from his holdings prior to the company's initial public offering [1]. Group 2: Stock Performance - Following the announcement of the share reduction, Koyuan Pharmaceutical's stock price opened lower and fell by over 10% on May 26 [2]. - The company's stock had previously surged from 19.59 yuan per share on September 24, 2022, to a peak of 58.66 yuan per share by October 29, 2022, before experiencing a continuous decline [2]. Group 3: Financial Performance - Koyuan Pharmaceutical's main business involves the research, production, and sales of chemical raw materials and their formulations, covering key disease areas such as diabetes, anesthesia, cardiovascular, and mental health [2]. - In 2023, the company reported a revenue increase of 1.07% but a net profit decrease of 15.6%. For 2024, revenue is expected to grow by 3.6%, while net profit is projected to decline by 21.54%, indicating a trend of increasing revenue but decreasing profitability [2]. - The company's net profit margin has decreased from 20.61% in 2022 to 13% in 2024, highlighting significant challenges in profitability [2]. - The net cash flow from operating activities turned negative in 2024, recording -60.5158 million yuan, compared to a positive 37.031 million yuan in 2023 [2]. Group 4: M&A Activity - Koyuan Pharmaceutical is currently engaged in an acquisition transaction, planning to issue shares and pay cash to acquire 99.42% of Shandong Hongjitang Pharmaceutical Group [3]. - The transaction involves multiple related parties, including its controlling shareholder, Lino Investment, indicating that it constitutes a related party transaction [4].